Back to Search Start Over

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.

Authors :
Driessen, Christoph
Besse, Lenka
Besse, Andrej
Hitz, Felicitas
Ribi, Karin
Berset, Catherine
Rondeau, Stephanie
Hawle, Hanne
Zander, Thilo
Müller, Rouven
Novak, Urban
Pabst, Thomas
Cantoni, Nathan
Betticher, Daniel
Mach, Nicolas
Rüfer, Axel
Mey, Ulrich
Samaras, Panagiotis
Source :
Blood. 11/8/2018, Vol. 132 Issue 19, p2097-2100. 4p.
Publication Year :
2018

Abstract

The article discusses the treatment effectiveness of combination drugs including nelfinavir, bortezomib, and dexamethasone in the treatment of proteasome inhibitor-refractory multiple myeloma. The treatment response in patients with relapsed and refractory multiple myeloma is accessed. Topics including the response rate of the drugs, the medication safety and efficacy of the treatment, and the survival analysis.

Details

Language :
English
ISSN :
00064971
Volume :
132
Issue :
19
Database :
Academic Search Index
Journal :
Blood
Publication Type :
Academic Journal
Accession number :
132912068
Full Text :
https://doi.org/10.1182/blood-2018-05-851170